Donald Jensen
#61,070
Most Influential Person Now
American physician
Donald Jensen's AcademicInfluence.com Rankings
Donald Jensenphilosophy Degrees
Philosophy
#10394
World Rank
#14244
Historical Rank
Logic
#8083
World Rank
#10057
Historical Rank
Download Badge
Philosophy
Donald Jensen's Degrees
- Doctorate Medicine Harvard University
Why Is Donald Jensen Influential?
(Suggest an Edit or Addition)According to Wikipedia, Donald Jensen is an American hepatitis C researcher and clinician, and Richard B. Capps Chair Emeritus, Rush University Medical Center. He attended high school in Springfield, IL, and was an undergraduate at the University of Illinois Champaign-Urbana. He attained his MD degree from the University of Illinois College of Medicine, and completed an internal medicine residency and chief medical resident at Rush University. He was subsequently a liver research fellow at King's College Hospital in London, UK, before returning to Rush as a faculty member. In 1999, he was appointed as the Richard B. Capps Professor of Medicine and chief of the section of hepatology. In 2005, he moved to the University of Chicago School of Medicine as professor of medicine and director of the Center for Liver Disease. In 2016, he assumed the position of Professor of Medicine at Rush University Medical Center.
Donald Jensen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy (2006) (543)
- Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
- Epidemiology of hepatitis B and C viruses: a global overview. (2010) (468)
- A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. (2010) (371)
- Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C (2001) (343)
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. (2013) (341)
- Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD) (2013) (251)
- Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. (1978) (212)
- Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial (1997) (177)
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b (2009) (176)
- Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose (2002) (153)
- Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. (2009) (138)
- Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. (1999) (127)
- Mechanism of action of ribavirin in the treatment of chronic hepatitis C. (2007) (124)
- Prevalence and Significance of Autoantibodies in Patients With Non-Alcoholic Steatohepatitis (2004) (109)
- High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials (2012) (104)
- Vanishing bile duct syndrome. (2008) (103)
- Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. (2001) (101)
- Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection (2015) (89)
- Characteristics of Hepatitis C in Renal Transplant Candidates (2002) (89)
- A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C (2012) (88)
- Current state of combined heart-liver transplantation in the United States. (2008) (86)
- A new era of hepatitis C therapy begins. (2011) (82)
- Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin (2008) (80)
- Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future (2011) (73)
- Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin (2008) (70)
- Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics, or nonfibrotics (1999) (65)
- Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. (2001) (65)
- Adult living donor liver transplantation: Preferences about donation outside the medical community (2001) (61)
- JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients (2013) (57)
- Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population (2010) (56)
- Ribavirin in the treatment of chronic hepatitis C (2008) (54)
- Immunogenicity of two recombinant hepatitis B vaccines in older individuals. (1993) (53)
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. (2003) (53)
- Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin (2006) (50)
- 1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL (2011) (50)
- Sticker shock and the price of new therapies for hepatitis C: Is it worth it? (2014) (48)
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients (2013) (47)
- Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B‐induced end stage liver disease (2006) (47)
- Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C (2004) (46)
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. (2015) (46)
- Future therapies for chronic hepatitis C (2013) (44)
- Herbal hepatoxicity from Chinese skullcap: A case report. (2012) (44)
- Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? (2015) (42)
- Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. (2004) (42)
- Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. (1997) (41)
- Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
- 13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS (2012) (40)
- Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. (2004) (39)
- Patients’ values for health states associated with hepatitis c and physicians’ estimates of those values (2001) (37)
- Co-Management Between Hospitalist and Hepatologist Improves the Quality of Care of Inpatients With Chronic Liver Disease (2014) (36)
- Hepatitis C virus infection and lung transplantation: a survey of practices. (1999) (35)
- Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. (2008) (34)
- Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents (2012) (34)
- Distributive justice and the arrival of direct‐acting antivirals: Who should be first in line? (2011) (33)
- Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer (2016) (31)
- Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration (1999) (31)
- Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari Syndrome or portal vein thrombosis (1999) (30)
- Adult living donor liver transplantation: Perspectives from 100 liver transplant surgeons (2003) (30)
- Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin (2005) (29)
- An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. (2001) (28)
- First phase hepatitis c viral kinetics in previous nonresponders patients (2003) (27)
- Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease (2012) (27)
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. (2015) (26)
- Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse (2012) (26)
- Serum enzymes associated with cholestasis. (2004) (26)
- Liver transplantation in patients with hepatitis B virus infection: Outcome in asian versus white patients (2001) (25)
- The benefit of paracentesis on hospitalized adults with cirrhosis and ascites (2016) (24)
- Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. (2003) (24)
- IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? (2012) (23)
- Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy (2019) (23)
- Patients' values for health states associated with hepatitis C and physicians' estimates of those values. (2001) (23)
- 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY (2011) (23)
- Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. (2012) (22)
- Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
- Case report. Amanita virosa acute hepatic necrosis: treatment with thioctic acid. (1982) (21)
- 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
- Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis (2016) (19)
- Pegylated interferon based therapy with second‐wave direct‐acting antivirals in genotype 1 chronic hepatitis C (2015) (18)
- The downstream financial effect of hepatology (2005) (17)
- Evaluation of Early Null Response to Pegylated Interferon and Ribavirin as a Predictor of Therapeutic Nonresponse in Patients Undergoing Treatment for Chronic Hepatitis C (2011) (17)
- Multiple abdominal vascular anomalies in a patient with Alagille syndrome. (2010) (17)
- Human immunodeficiency virus and coinfection with hepatitis B and C. (2014) (16)
- Physicians' preference values for hepatitis C health states and antiviral therapy: A survey (2001) (16)
- 1205 SVR-12 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNa-2A/RBV: INTERIM ANALYSIS FROM THE JUMP-C STUDY (2012) (15)
- Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy (2014) (15)
- Interferon‐free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study (2016) (15)
- A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients (2003) (15)
- The plasma membrane origin of liver-specific protein (LSP). (2008) (15)
- Duodenal Varices: A Case Report and Review of the Literature (1995) (14)
- A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres (2004) (14)
- Treatment of hepatitis C virus and HIV co-infections. (2001) (14)
- Hepatobiliary manifestations of critically ill and postoperative patients. (2011) (14)
- Transjugular intrahepatic portosystemic shunt in nonliver transplant candidates: is it indicated? (1995) (14)
- 1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY (2012) (13)
- Cerebral edema and hyperammonemia after transjugular intrahepatic portosystemic shunt placement in a cirrhotic patient. (2008) (13)
- Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. (2002) (13)
- Use of immune function test in monitoring immunosuppression in liver transplant recipients (2012) (12)
- Generic medications for hepatitis C (2016) (12)
- Future directions in therapy for chronic hepatitis C (2008) (12)
- 7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3 (2012) (11)
- Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2) (2014) (11)
- Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C (2014) (11)
- Clinical impact of treatment timing for chronic hepatitis C infection: a decision model (2015) (9)
- Evaluation of abnormal liver tests. (1994) (8)
- 805 HCV-RNA STATUS AT WEEK 12 OF TREATMENT WITH PEGINTERFERON ALFA-2A/RBV PREDICTS SVR IN PATIENTS WITH PRIOR NON-RESPONSE TO PEGYLATED INTERFERON ALFA-2B/RBV: RESULTS FROM REPEAT STUDY (2008) (8)
- Use of amylase isoenzymes in laboratory evaluation of hyperamylasemia (1987) (8)
- 11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study (2006) (7)
- Serum alanine aminotransferase levels and prevalence of hepatitis A, B, and delta in outpatients. (1987) (7)
- Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus (2014) (7)
- Multiple progressive focal nodular hyperplasia lesions of liver in a patient with hemosiderosis. (2010) (7)
- Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
- 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
- S1937 Type of Response to Prior Pegylated Interferon Alfa-2b (12KD)/RBV Predicts Subsequent Response to Retreatment with Peginterferon Alfa-2a (40KD)/RBV (2008) (6)
- Faster than a speeding bullet (2014) (5)
- 818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR (2013) (5)
- Is the HCV pipeline heading in the right direction? (2013) (5)
- A call to action: The need for hepatology‐focused educational interventions in Internal Medicine Residency training (2015) (5)
- Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology (2016) (5)
- Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies (2012) (5)
- Tu1066 Birth Cohort HCV Screening at Is Lower in the Emergency Department Than the Outpatient Setting (2015) (4)
- 721 Prevalence and clinical features associated with autoantibodies in nonalcoholic steatohepatitis (NASH) (2003) (4)
- Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done? (2009) (4)
- IS LAMIVUDINE BENEFICIAL IN HBSAG+ PATIENTS AWAITING LIVER TRANSPLANTATION? EXPERIENCE IN 182 NORTH AMERICAN PATIENTS. (1999) (4)
- 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results (2014) (3)
- Antibodies directed against human liver specific membrane lipoprotein (LSP) in marmosets experimentally infected with the hepatitis A virus. (1984) (3)
- Prevalence of HBV precore and core promotor variants in the United States — results of a nation-wide study (2002) (3)
- A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy (2014) (3)
- Advances in combination regimens in the management of HCV infection. (2014) (3)
- Marked Flare in Hepatic Aminotransferases During Treatment with Pegylated Interferon for Chronic Hepatitis C, Genotype 2: A Case Report (2009) (3)
- 797 EASY TO ASSESS ON-TREATMENT PARAMETERS CORRELATE WITH DEGREE OF VIROLOGICAL RESPONSE AFTER 12 WEEKS OF TREATMENT (2008) (3)
- Chronic liver disease manifesting as Waldenström's macroglobulinemia. (1982) (3)
- HBV and HCV Co-Infection (2002) (3)
- 611 Poor prognostic factors in heavier patients with chronic hepatitis C (CHC) result in less favourable treatment outcomes (2006) (3)
- Liver Dysfunction in Critically Ill Patients (2015) (3)
- P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS (2014) (3)
- Controversies in Hepatology: The Experts Analyze Both Sides (2011) (2)
- P1226 NS3 Q80K DID NOT IMPACT EFFICACY OR TREATMENT-EMERGENT RESISTANCE PATTERNS IN HCV GENOTYPE 1-INFECTED PATIENTS RECEIVING FALDAPREVIR + PEGINTERFERON/RIBAVIRIN IN THREE PHASE III TRIALS (2014) (2)
- Advances in cholestatic liver disease. Preface. (2008) (2)
- Serological markers of autoimmunity in patients infected with hepatitis C virus: impact of HIV co‐infection (2005) (2)
- Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment (2013) (2)
- Acute Hepatitis B: A Further Serological Characterization (1982) (2)
- Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. (2006) (2)
- Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction (2014) (2)
- 806 TYPE OF RESPONSE TO PRIOR PEGYLATED INTERFERON ALFA-2B (12KD)/RBV PREDICTS SUBSEQUENT RESPONSE TO RETREATMENT WITH PEGINTERFERON ALFA-2A (40KD)/RBV (2008) (2)
- Liver and Biliary Diseases (1993) (2)
- Transfusions to tattoos The danger of hepatitis C (1996) (2)
- 583 Safety of peginterferon α-2a (40KD) (PEGASYS®) [PEG-IFNα-2a (40KD)] plus ribavirin (COPEGUS®) among pegylated interferon α-2b (12KD)/ribavirin non-responders: Interim analysis of the repeat study (2006) (2)
- P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALS (2014) (2)
- Hepatitis C: current and future therapies. (2008) (2)
- P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS (2014) (2)
- The FDA, bridging data, and hepatitis C (2013) (2)
- O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 (2014) (2)
- Future therapies for chronic hepatitis C (2013) (2)
- 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY (2012) (2)
- Liver Transplantation in Severly Obese Patients: A Single Center Experience (2005) (1)
- PF-03491390 INHIBITS LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION VIA SUPPRESSION OF PRO-APOPTOTIC CASPASE-ACTIVA- TION. (2007) (1)
- Diseases of the Liver, ed 5 (1982) (1)
- 637 Practitioners Advise Therapy Outside of HBV Treatment Guidelines More Frequently in HBeAg Positive Patients and More Often When Using AASLD Compared to EASL Guidelines (2010) (1)
- Interferon alfa-2a for cryoglobulinemia associated with hepatitis C virus. (1994) (1)
- Sustained viral response after interferon‐based therapy in chronic hepatitis C: more evidence to support a life‐long cure (2009) (1)
- S1831 Adherence to Standard of Care Measures in Suspected Acute Variceal Bleeding (2009) (1)
- The long‐term horizon: Patients who will remain untreated in the era of triple therapy (2012) (1)
- Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (1)
- [614] HOST AND VIRAL BASELINE CHARACTERISTICS IN HEPATITIS C NAIVE AND NON-RESPONDER PATIENTS: COMPARISON OF THREE LARGE RANDOMISED MULTINATIONAL TRIALS (2007) (1)
- Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin (2015) (0)
- 897 CONSENSUS RECOMMENDATIONS FOR VIROLOGIC NOMENCLATURE IN DAA CLINICAL TRIALS (2012) (0)
- P1227 FALDAPREVIR EFFICACY IN HCV GENOTYPE-1-INFECTED PATIENTS IN FOUR PHASE 3 TRIALS: ANALYSIS BY NS3 BASELINE POLYMORPHISMS, GENOTYPE-1 SUBTYPE AND GENOTYPE-1A CLADES (2014) (0)
- 1158 SUBTYPE 1B DOES NOT CONFER A TREATMENT ADVANTAGE TO HCV INFECTED AFRICAN AMERICAN PATIENTS TREATED WITH PEG+RBV (2011) (0)
- P.259 Retreatment with peginterferon alpha-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients in whom pegylated interferon alpha-2b (12KD)/ribavirin has failed: planned week-12 efficacy and safety analysis of the repeat study (2006) (0)
- 620 IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) (2009) (0)
- Similarities and Differences Between REPEAT and EPIC3. Authors' reply (2009) (0)
- S1909 Clinical and Liver Histological Differences in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) with and Without Diabetes Mellitus (DM) (2008) (0)
- Retreatment of chronic hepatitis C in previous non-responders and relapsers (2007) (0)
- 240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HCV Mono-Infected Patients and No Dose or Population (Treatment-Naïve/Relapser) Effect: Pooled Analysis of Faldaprevir Phase III Trials (2014) (0)
- M1788 Identifying Patients Infected with HCV Genotype 1 Who May Benefit from Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks (2009) (0)
- FACTORS IMPLICATED IN RECEIVING THERAPY IN PATIENTS WITH HEPATITIS C ± HIV CO-INFECTION IN A LOWER SOCIAL ECONOMIC GROUP: 302 (2004) (0)
- Subtype 1b Does Not Confer a Response Advantage to HCV Infected African American Patients Treated With PEG+RBV (2011) (0)
- Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribavirin in Three Phase III Trials (2014) (0)
- P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION (2014) (0)
- Sa1080 Short-Term Outcomes in Chronic Hepatitis C Treated With Triple Therapy: Impact on Patients With Advanced Fibrosis (2012) (0)
- A Case of Rapid Decline in Alcohol‐Associated Liver Disease (2021) (0)
- 988 Severe Thrombocytopenia Predicts Lower Survival Rate and Higher Transplant Rate in Patients With Liver Cirrhosis (2019) (0)
- Excessive Reduction in Hvpg is Predictive of Mortality After Transjugular Intrahepatic Portosystemic Shunt (TIPS) (2011) (0)
- SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT (2014) (0)
- M1789 Racial Differences in Globulin Levels in Patients with Hepatitis C and Virologic Response to Pegylated Interferon and Ribavirin (2009) (0)
- Abstract 2144: Retinoid and carotenoid depletion in patients at high-risk for liver cancer (2014) (0)
- Comprar Cholestasis, An Issue of Clinics in Liver Disease | Donald M. Jensen | 9781416058380 | Saunders (2008) (0)
- M1890 Is There a Justification for the Attitudes and Practices of Hepatologists and Transplant Surgeons Regarding Transplantation in Patients with Alcoholic Liver Disease (2008) (0)
- P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS (2014) (0)
- Su1229 Divergence From AASLD HCC Surveillance Guidelines Leads to Unnecessary Testing and Radiation Exposure (2012) (0)
- Human Immunodeficiency Virus and Coinfection with Hepatit is B and C (0)
- The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. (2012) (0)
- Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (0)
- HCV Eradication: Implications for Disease Resolution (2011) (0)
- Sa1510 EVALUATION OF A HBV PREGENOMIC RNA (PGRNA) ASSAY AND ITS UTILITY IN THE MANAGEMENT OF PATIENTS WITH HBV. (2020) (0)
- The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents (2022) (0)
- S1840 Refractory Spontaneous Bacterial Peritonitis: A Retrospective Study (2009) (0)
- Maintenance Therapy with Oral Antiviral Agents (2012) (0)
- Su1020 Faldaprevir Efficacy in HCV Genotype-1-Infected Patients in Four Phase III Trials: Analysis by Ns3 Baseline Polymorphisms, Genotype-1 Subtype and Genotype-1A Clades (2014) (0)
- Interhepatic calculi. Edited by Kunio Okuda. Fumio Nakayama and John Wong. 340 pp. + xii. New York: Alan R. Liss, Inc., 1984. $78.00 (1985) (0)
- Tu1002 Non Liver Disease-Related Factors Significantly Impact “Liver Disease-Specific” Quality of Life Scores From the Chronic Liver Disease Questionnaire (CLDQ) (2014) (0)
- Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Exploratory Study of Pooled Data From Phase III Trials (2014) (0)
- 403 RACIAL DIFFERENCES IN GLOBULIN LEVELS IN PATIENTS WITH HEPATITIS C AND VIROLOGIC RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN (2009) (0)
- Treatment duration for genotypes 2 and 3: still confusing after all these years. (2010) (0)
- Comprar Controversies In Hepatology. The Experts Analyze Both Sides | Donald Jensen | 9781556429507 | Slack Incorporated (2011) (0)
- Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
- News and notices (2005) (0)
- The AASLD: A History of the First Ten Years and its Presidents. (2022) (0)
- Similarities and Differences Between REPEAT and EPIC3 (2009) (0)
- Following AASLD Guidelines for HCC Screening in HBV is Limited by Adherence and Results in Additional Tests With Potential Radiation Risk (2011) (0)
- S2454 Eosinophilic Cholangitis – An Uncommon Cause of Elevated Liver Enzymes (2020) (0)
- S1938 HCV-RNA Status At Week 12 of Treatment with Peginterferon Alfa-2a/RBV Predicts SVR in Patients with Prior Non-Response to Pegylated Interferon Alfa-2b/RBV: Results from Repeat Study (2008) (0)
- 706 DIVERGENCE FROM AASLD HCC SURVEILLANCE GUIDELINES LEADS TO UNNECESSARY TESTING AND RADIATION EXPOSURE (2012) (0)
- Su1062 Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon α-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12 (2014) (0)
- Induction of IL-1 Ra in Resistant and Responsive Hepatitis C Patients Following Treatment with IFN-con 1 (2004) (0)
- Duod . enal Varices : A Case Report and Review of the Literature (2014) (0)
- PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES (2009) (0)
- SUBMITTED, NOT PRESENTED: LIVER (2021) (0)
- Su1056 Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Pooled Data From Phase III Trials (2014) (0)
- Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies (2014) (0)
- Erratum: "R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin" (Hepatology (2008) vol. 48 (385-397) 10.1002/hep.22357) (2008) (0)
- 892 ANEMIA PREDICTS SUSTAINED VIROLOGIC RESPONSE IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN FOUR CLINICAL TRIALS (2013) (0)
- Sa1848 Protein Biomarkers Reactive With Hepatocellular Carcinoma (HCC) Sera Serve As a Signature for Hepatocellular Carcinoma (2015) (0)
- 619 IDENTIFYING PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO MAY BENEFIT FROM EXTENDED PEGINTERFERON ALFA-2A/RIBAVIRIN THERAPY BEYOND 48 WEEKS (2009) (0)
- 1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies (2014) (0)
- P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS (2014) (0)
- Comparison of outcomes, treatment selection and completion in hepatitis C patients in academic and community based ambulatory treatment centers (2001) (0)
- 575 Retreatment with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in pegylated interferon α-2b (12KD)/ribavirin non-responders with cirrhosis/advanced fibrosis: Repeat interim analysis (2006) (0)
- Safety of peginterferon alpha-2a (40KD) (PEGASYS (R)) [PEG-IFN alpha-2a (40KD)] plus ribavirin (COPEGUS (R)) among pegylated interferon alpha-2b (12KD)/ribavirin non-responders: Interim analysis of the repeat study (2006) (0)
- 197 REFRACOTRY SPONTANEOUS BACTERIAL PERITONITIS: A RETROSPECTIVE STUDY OF THE UNIVERSITY OF CHICAGO EXPERIENCE (2009) (0)
- 147 EXCESSIVE REDUCTION IN HVPG IS PREDICTIVE OF MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) (2011) (0)
- P0353 : Protein biomarkers reactive with HCC sera serve as a signature for hepatocellular carcinoma (HCC) (2015) (0)
- Hepatitis C. (1995) (0)
- T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies (2010) (0)
- Diastolic Dysfunction Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation (2011) (0)
- P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES (2014) (0)
- S1941 Easy to Assess On-Treatment Parameters Correlate with Degree of Virological Response After 12 Weeks of Treatment (2008) (0)
- 170 DIASTOLIC DYSFUNCTION PREDICTS MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) CREATION (2011) (0)
- The rapid first phase decline in hepatitis C viremia is lower in previous nonresponders compared to treatment naive patients (2001) (0)
- 485 Screening for Zinc Deficiency is Necessary in the Management of Patients With Cirrhosis (2014) (0)
- P466 SCREENING FOR ZINC DEFICIENCY IS NECESSARY IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS (2014) (0)
- P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12 (2014) (0)
- DDDT_A_172512 2565..2577 (2019) (0)
- Abstract 2821: Joint relationship between iron and retinoids in patients at high-risk for liver cancer (2015) (0)
- Physicians' utility assessment of health states associated with chronic hepatitis C (2000) (0)
This paper list is powered by the following services:
Other Resources About Donald Jensen
What Schools Are Affiliated With Donald Jensen?
Donald Jensen is affiliated with the following schools:
